Hadassah

Drug Company Collaborates with Hadassah Liver Specialist in Fighting Liver Disease

Wednesday, Jan 10 2018

Illustration of the positive impact of Namodenoson, as compared to treatment of animals with a placebo (“vehicle”)

Dr. Rifaat Safadi, head of the Hadassah Medical Organization’s Liver Unit, in its Institute of Gastroenterology and Liver Diseases, is collaborating with Can-Fite BioPharma Ltd. to explore further the healing effects of a new drug that has proven in preclinical studies to mitigate inflammatory diseases of the liver, such as NASH (non-alcoholic steatohepatitis).

The new drug called Namodenoson, Dr. Safadi says, “is unique among today’s NASH drugs under development due to its excellent safety profile and the positive effect on steatosis (accumulation of fat in the liver), inflammation, and fibrosis (liver scarring, which results from dying of liver cells, also referred to as ballooning).”  Improvement in these parameters translates into a significant anti-NASH effect.

Namodenoson has been granted Orphan Drug Designation in the United States and Europe and Fast Track Designation as a second-line treatment for hepatocellular cancer by the United States Food and Drug Administration. It has the potential to be effective in treating other cancers, including colon and prostate cancer, as well as melanoma.

Can-Fite has initiated enrollment for a Phase II study with Namodenoson in NASH and NAFLD (non-alcoholic fatty liver disease) patients who show evidence of active inflammation. The focus will be on measuring the drug’s anti-inflammatory effect and its success in reducing fat in the liver.

A prolific researcher, renowned for his work with NASH, Dr. Safadi is also a member of Can-Fite’s Clinical Advisory Board. “We are privileged to work with Dr. Safadi to further study and advance the drug’s mechanism of action,” notes Pnina Fishman, PhD, Founder and Chief Executive Officer of Can-Fite.

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, Dec 10 2018

A Nurses Council Celebration in Israel: The Milestone Mission

We were honored to meet so many dynamic Hadassah nurses, some longtime and some new members--all of us excited to be together to celebrate the 100th anniversaries of the Hadassah Medical Organization, the Henrietta Szold Hadasssah-Hebrew University Nursing School and HMO's Department of Ophthalmology. And Israel's 70th

READ MORE ›
alt_text

Wednesday, Dec 5 2018

Ending the Violence Against Women: Hadassah Staff Joins Nationwide Protests

On December 4, employees from both Hadassah Hospital Ein Kerem and Hadassah Hospital Mount Scopus rallied to end violence against women. “Together we will banish the darkness and return the light to all women,” read banners held by the participants.

READ MORE ›
alt_text

Wednesday, Dec 5 2018

Prof. Chowers’ Long and Meaningful Hadassah Connections

Sophie Szold, mother of Hadassah founder Henrietta, wept when she saw children with flies in their eyes on their maiden trip to pre-state Israel in 1909. Those children had trachoma, endemic in the Middle East in those days.

READ MORE ›
alt_text

Tuesday, Dec 4 2018

No Ovaries? Mystery Solved By Hadassah Endocrinologist

A few years ago, a mother brought her teenage daughter to see Prof. David Zangen, Director of Pediatric Endocrinology at the Hadassah Medical Organization.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More